Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Envista HoldingsNVST -1.75%79 Debt-to-Equity is 0.52 as of Jun. 2026, which is 21% above its 10-year median of 0.43. GuruFocus rates NVST with a GF Score™ of 79/100 and a GF Value™ of $23.94 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 705 Medical Devices & Instruments companies, Envista Holdings ranks worse than 69.36% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Envista Holdings's Debt-to-Equity or its related term are showing as below:
NVST'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.36 Med: 0.43 Max: 0.62
Current: 0.52
During the past 10 years, the highest Debt-to-Equity Ratio of Envista Holdings was 0.62. The lowest was 0.36. And the median was 0.43.
NVST's Debt-to-Equity is ranked worse than 69.36% of 705
companies
in the Medical Devices & Instruments industry
Industry Median: 0.23
vs NVST: 0.52
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Envista Holdings Debt-to-Equity Related Terms
Envista Holdings Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Envista Holdings's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NVST vs MMSI, ICUI, MMED: Debt-to-Equity Comparison
For the Medical Instruments & Supplies subindustry, Envista Holdings's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Envista Holdings Debt-to-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Envista Holdings's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Envista Holdings's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Envista Holdings (NVST) has a Debt-to-Equity of 0.52 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Envista Holdings and its competitors. This is 21% above median its historical median of 0.43. Over the past decade, Envista Holdings' Debt-to-Equity has ranged from 0.36 to 0.62. According to the industry distribution chart, Envista Holdings ranks #489 out of 705 companies in the Medical Devices & Instruments industry, placing it in the top 69.4%.
Is Envista Holdings' Debt-to-Equity too high?
Envista Holdings' current Debt-to-Equity of 0.52 is 21% above median its 10-year median of 0.43. Over the past 10 years, this metric has ranged from a low of 0.36 to a high of 0.62. The Medical Devices & Instruments industry median Debt-to-Equity is 0.23. Envista Holdings' value of 0.52 is 126.1% above this industry median. Based on the distribution chart, Envista Holdings ranks #489 out of 705 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Envista Holdings has a GF Score™ of 79/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Envista Holdings' Debt-to-Equity compare to MMSI and ICUI?
According to the Medical Devices & Instruments industry distribution chart, Envista Holdings ranks #489 out of 705 companies for Debt-to-Equity. This places Envista Holdings in the lower half of its industry. The industry median Debt-to-Equity is 0.23. Envista Holdings' value of 0.52 is 126.1% above this benchmark. Historically, Envista Holdings' own Debt-to-Equity has ranged from 0.36 to 0.62 over the past decade. While the company's 10-year median is 0.43 vs. the industry median of 0.23, Envista Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Devices & Instruments company?
The median Debt-to-Equity among Medical Devices & Instruments companies is 0.23, based on 705 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Envista Holdings's current Debt-to-Equity of 0.52 is 126.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Envista Holdings and its competitors. For the Medical Devices & Instruments industry, the median Debt-to-Equity is 0.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Envista Holdings's current Debt-to-Equity is 0.52, which is 21% above median its own 10-year median of 0.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Envista Holdings stock overvalued right now?
Based on GuruFocus' analysis, Envista Holdings (NVST) is currently considered Modestly Overvalued. The stock's GF Value™ is $23.94, compared to a current price of $28.13 — trading 17.5% above its estimated fair value. The current Debt-to-Equity is 0.52, which is 21% above median its 10-year median of 0.43 and 126.1% above the Medical Devices & Instruments industry median of 0.23. Envista Holdings' overall GF Score™ is 79/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Envista Holdings (NVST), the current Debt-to-Equity is 0.52 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Envista Holdings (NVST) Overvalued in 2026?
Based on GuruFocus' analysis, Envista Holdings stock appears to be overvalued.
The current stock price of $28.13 is trading 17.5% above its estimated GF Value™ of $23.94.
GuruFocus considers Envista Holdings to be Modestly Overvalued.
Key valuation signals for NVST:
Debt-to-Equity: 0.52 (21% above median its 10-year median of 0.43)
GF Value™: $23.94 vs. price of $28.13 (17.5% above fair value)
Industry Position: 126.1% above the Medical Devices & Instruments median (#489 of 705)
No single metric tells the full story. See the NVST stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Envista Holdings Corp is a dental products company. It develops, manufactures, and markets portfolios of dental consumables, equipment, and services to dental professionals. The company's business consists of two segments; Specialty Products & Technologies and Equipment & Consumables. The company's Specialty Products & Technologies segment, which derives key revenue, develops, manufactures, and markets dental implant systems, including regenerative solutions, dental prosthetics, and associated treatment software and technologies, as well as orthodontic bracket systems, aligners, and lab products. Geographically, the company generates a majority of its revenue from North America, followed by Western Europe and other developed and emerging markets.
79GF Score
Get the complete analysis for NVST
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NVST has been successfully added to your 
